Victoza Lawsuits in 2026: the Dismissed Cancer MDL, the Claims Still Alive — and Who Can File?

Victoza lawsuits in 2026 tell a split story: the first wave of pancreatic-cancer claims was dismissed and stayed dismissed on appeal, while newer claims over stomach paralysis and vision loss are still moving. Knowing which wave your case belongs to is the first step.

  • Victoza (liraglutide) received its initial U.S. approval in 2010 as an addition to diet and exercise for blood-sugar control in adults with type 2 diabetes.
  • Its label carries a boxed warning for thyroid C-cell tumors seen in rats and mice at clinically relevant exposures; whether it causes such tumors in humans has not been determined.
  • Victoza is contraindicated — meaning it must not be used — in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
  • The incretin pancreatic-cancer litigation, MDL 2452, began with 53 actions consolidated on August 26, 2013, grew to roughly 970 cases, and was dismissed in March 2021, with the appeal decided for Novo Nordisk in 2022.
  • Victoza has not been recalled, and a generic version distributed by Teva has been available since June 2024.

What Victoza Is — and Why It Carries a Boxed Warning

Victoza is the brand name for liraglutide, an injectable medicine in the GLP-1 class — drugs that mimic a natural gut hormone to increase insulin production and control blood sugar. The FDA approved it in January 2010 for adults with type 2 diabetes, as an addition to diet and exercise, and later for patients aged 10 and older.

From the start, its label carried the FDA’s strongest warning, a boxed warning, for the risk of thyroid C-cell tumors. In both male and female rats and mice, liraglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. The label states plainly that it is unknown whether Victoza causes thyroid C-cell tumors, including medullary thyroid carcinoma — a rare thyroid cancer — in humans, because human relevance could not be ruled out by clinical or nonclinical studies.

That is why the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2, a hereditary condition that raises the risk of endocrine tumors. The label also warns about pancreatitis — inflammation of the pancreas — including postmarketing reports of fatal and nonfatal hemorrhagic or necrotizing pancreatitis, and it says the drug should not be restarted if pancreatitis is confirmed.

The Pancreatic-Cancer MDL: Filed, Consolidated, Dismissed

The first wave of Victoza litigation began around 2013, alongside claims over other incretin drugs such as Byetta and Januvia. Patients alleged the drugs caused pancreatic cancer and pancreatitis, that the makers failed to warn about the cancer risk, and that pancreatic cancer was not even mentioned in the labeling.

On August 26, 2013, the Judicial Panel on Multidistrict Litigation consolidated 53 actions from seven federal districts into MDL 2452, In re Incretin-Based Therapies Products Liability Litigation, before Judge Anthony J. Battaglia in the Southern District of California. Multidistrict litigation, or MDL, is a procedure that groups similar federal cases before one judge for pretrial proceedings while each plaintiff keeps an individual claim. The docket eventually grew to roughly 970 filed cases involving close to 1,000 plaintiffs, with a parallel state proceeding of more than 300 cases in Los Angeles County.

That wave ended against the plaintiffs. The cases were dismissed in March 2021 after a judge ruled there was not enough evidence to link Victoza to pancreatic cancer, and in 2022 the appeals court sided with Novo Nordisk, so the cases were not revived. Anyone whose Victoza story is only about pancreatic cancer should understand this history before spending money or hope on a new filing: the central causation theory has already been tested and rejected in that MDL.

The Claims Still Alive in 2026: Gastroparesis and Vision Loss

Litigation did not end with the cancer MDL; it moved to different injuries. Victoza is now among the GLP-1 drugs named in lawsuits alleging the makers did not adequately warn about gastroparesis — delayed stomach emptying, often described as stomach paralysis — and intestinal blockages. Those gastrointestinal claims, covering Victoza alongside Ozempic, Wegovy, and Mounjaro, have been consolidated in the Eastern District of Pennsylvania, as described in our Ozempic gastroparesis MDL guide.

The newest front is vision loss. A 2025 research letter in JAMA Ophthalmology reported that semaglutide was associated with a 39% higher risk of NAION — non-arteritic anterior ischemic optic neuropathy, a sudden loss of vision from reduced blood flow to the optic nerve — while liraglutide was associated with a 25% higher risk. Lawyers are seeking to consolidate NAION vision-loss cases, including Victoza and Saxenda cases, into multicounty litigation in New Jersey. These cases are in their early stages, with no settlements or trials yet, and a research association is not proof that the drug caused any individual person’s vision loss.

The lesson for readers is to match the injury to the litigation: gastroparesis and vision-loss claims are live questions in 2026, while pancreatic-cancer claims carry the weight of a dismissal. Our GLP-1 lawsuit comparison across every named drug shows how the same class of medicines produced very different case histories.

The Thyroid Warning, Explained Plainly

The thyroid boxed warning often confuses patients, because it is based on animal findings rather than proven human cases. Rodents developed thyroid C-cell tumors at exposures comparable to human doses, and the effect grew with dose and duration. Human studies could neither confirm nor rule out the risk, so the FDA required the strongest warning and a ban on use in the highest-risk groups, rather than waiting for certainty.

The label also notes that monitoring with blood calcitonin tests or thyroid ultrasound during trials may have increased unnecessary thyroid surgeries, and that it is unknown whether such monitoring reduces human risk. Patients are counseled to report symptoms of thyroid tumors, such as a lump in the neck, difficulty swallowing, difficulty breathing, or persistent hoarseness. If you have a family history of medullary thyroid carcinoma and were prescribed Victoza anyway, that fact alone is worth a lawyer’s attention, because it goes to the label’s clearest prohibition.

Can You Still File in 2026?

It depends on the injury and the state. Gastroparesis and vision-loss claims are recent theories, so their filing windows are being tested now. Pancreatic-cancer claims face both the 2021 dismissal and ordinary time limits: prescription-drug statutes of limitation typically range from 1 to 6 years by state, most often 2 to 3 years, usually starting under a discovery rule when the person knew or should have known of the connection.

A further wrinkle is the generic. Since June 2024, generic liraglutide distributed by Teva has been available, and warning duties for generic makers have been litigated differently from those for brand makers. Whether you took brand Victoza or generic liraglutide, and when, is one of the first questions any reviewing lawyer will ask. The Byetta pancreatitis claims show how an older incretin case history frames these questions.

Do not calculate a deadline alone. Wrongful-death claims use a separate clock from the date of death, minors’ deadlines may be paused, and some states impose outer statutes of repose that bar claims a fixed number of years after the product was sold, regardless of discovery.

What Evidence Strengthens a Claim

For gastroparesis claims, the core records are the prescription history, gastric-emptying study results, and any hospitalization for vomiting, blockage, or surgery. For vision-loss claims, the core records are ophthalmology findings, the timing of the NAION diagnosis against Victoza use, and any record of prior eye disease. For thyroid claims, the core records are the diagnosis, family history, and proof the contraindication was known or should have been checked.

Across all three, the same foundations apply: pharmacy records proving the exact product and dates, medical records showing health before and after Victoza, and a dated timeline of symptom onset. Most drug-injury firms review cases free of charge and work on contingency, with the fee taken as a percentage of any recovery only if the case succeeds. Compensation varies widely by case, and most settlements are confidential.

Who Benefits From This — and Who Does Not

This topic matters most to four kinds of reader. First, a Victoza patient diagnosed with gastroparesis or an intestinal blockage after starting the drug. Second, a patient who suffered sudden vision loss diagnosed as NAION during or after liraglutide use. Third, a patient with a personal or family history of medullary thyroid carcinoma, or MEN 2, who was prescribed Victoza despite the label’s contraindication. Fourth, a family pursuing a claim for a loved one whose serious injury fits one of these patterns and is documented in medical records.

It matters less, or not at all, to others. A patient who used Victoza for years with good blood-sugar control and no listed injury has no claim. A pancreatic-cancer-only claim faces the dismissed MDL and a causation ruling that went against plaintiffs, so expectations should be set by that history, not by advertising. And anyone hoping for a fast, certain payout should know that the newest vision-loss cases have no settlements or trials yet, and that individual claims can end with no recovery. If your story is about blood-sugar control rather than injury, the useful next step is a conversation with your clinician, not a lawyer.

Frequently Asked Questions

Who benefits from a Victoza lawsuit?

People most likely to benefit are Victoza or generic liraglutide patients diagnosed with gastroparesis or an intestinal blockage, patients diagnosed with NAION vision loss during or after use, and patients with a personal or family history of medullary thyroid carcinoma or MEN 2 who were prescribed the drug despite its contraindication.

Who does not benefit, or who is not eligible?

Patients who used Victoza without any listed injury do not have a claim. Pancreatic-cancer-only claims are also very difficult after the MDL dismissal in March 2021 and the 2022 appeal decision for Novo Nordisk, because the causation theory was tested and rejected there.

How do I start a Victoza claim?

Start in four steps: first, gather pharmacy records showing brand Victoza or generic liraglutide and the dates used; second, collect the records for your specific injury, such as gastric-emptying results or ophthalmology findings; third, write a dated timeline of use and symptom onset; fourth, ask a drug-injury lawyer for a free case review and bring those records, and ask the lawyer to confirm your state deadline.

Was Victoza recalled?

No. Victoza has not been recalled and remains available, and a generic version distributed by Teva has been available since June 2024. Its label still carries the boxed warning for thyroid C-cell tumors.

What happened to the Victoza pancreatic-cancer MDL?

The incretin pancreatic-cancer cases were consolidated as MDL 2452 in the Southern District of California, growing to roughly 970 cases. They were dismissed in March 2021 because a judge ruled there was not enough evidence linking Victoza to pancreatic cancer, and in 2022 the appeals court sided with Novo Nordisk, so the cases were not revived.

What is NAION, and why is it part of 2026 Victoza claims?

NAION is non-arteritic anterior ischemic optic neuropathy, a sudden vision loss caused by reduced blood flow to the optic nerve. A 2025 research letter reported liraglutide was associated with a 25% higher risk of NAION, and lawyers are seeking to consolidate NAION cases, including Victoza cases, into multicounty litigation in New Jersey. These cases are early-stage, with no settlements or trials yet, and an association in a study does not prove causation in any individual case.

This article provides general information only. It is not legal or medical advice. Lawsuit eligibility and deadlines depend on your state, your injury, and your facts, so speak to a licensed attorney in your state and to your clinician before making any decision about treatment or a claim. For plain-language explainers on drug-safety topics, see the Problem Solved channel.

Watch on YouTube

Problem Solved on YouTube